Scarica l'app Stockscreener
50.23
1.91%
0.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$49.29
Aprire:
$48.48
Volume 24 ore:
2.75M
Relative Volume:
1.12
Capitalizzazione di mercato:
$4.79B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-17.94
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-4.38%
1M Prestazione:
-30.54%
6M Prestazione:
+35.79%
1 anno Prestazione:
+8.51%
Intervallo 1D:
$48.02
$51.45
Intervallo di 1 settimana:
$48.02
$55.77
Portata 52W:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
50.23 | 4.70B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Del Sette Capital Management LLC Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG Faces Stock Price Slide - TipRanks
Rockefeller Capital Management L.P. Purchases 24,853 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Acquired by Geode Capital Management LLC - MarketBeat
CRISPR Therapeutics Hits Day High with 8.24% Surge in Stock Price - Markets Mojo
Can CRISPR Therapeutics AG stock deliver surprise earnings beatWeekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
CRISPR Therapeutics Hits Day Low at $48.24 Amid Price Pressure - Markets Mojo
Is CRISPR Therapeutics AG (1CG) stock undervalued after correctionJuly 2025 Update & Fast Entry High Yield Tips - newser.com
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - Finviz
How CRISPR Therapeutics AG stock performs after earningsLong Setup & Stepwise Entry and Exit Trade Signals - newser.com
How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is CRISPR Therapeutics AG (1CG) stock prepared for digital transition2025 Major Catalysts & High Conviction Trade Alerts - newser.com
SG Americas Securities LLC Acquires 9,141 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Is CRISPR Therapeutics AG (1CG) stock worth holding before Fed meetingTrend Reversal & Consistent Growth Stock Picks - newser.com
Alteri Wealth LLC Takes $269,000 Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Will CRISPR Therapeutics AG (1CG) stock keep high P E multiplesJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Is CRISPR Therapeutics AG stock recession proof2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Has CRISPR Therapeutics AG found a price floorQuarterly Market Summary & Risk Controlled Daily Trade Plans - newser.com
Why CRISPR Therapeutics AG (1CG) stock is listed among top recommendationsEarnings Recap Report & Verified Chart Pattern Trade Signals - newser.com
Is CRISPR Therapeutics AG (1CG) stock a buy on weaknessJuly 2025 Action & AI Enhanced Trading Alerts - newser.com
Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - news.bloomberglaw.com
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? - Barchart.com
How to build a dashboard for CRISPR Therapeutics AG stockEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com
CRISPR Therapeutics stock pops following disclosure of RFK Jr. investment - MSN
Is CRISPR Therapeutics AG showing signs of accumulationJuly 2025 Fed Impact & Smart Money Movement Tracker - newser.com
What to do if you’re stuck in CRISPR Therapeutics AGWeekly Trade Analysis & Proven Capital Preservation Tips - newser.com
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - The Motley Fool
Reversal indicators forming on CRISPR Therapeutics AG stock2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Published on: 2025-11-18 23:19:07 - newser.com
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):